tetano
Editor, Senior Moderator
Microbiol Spectr
. 2023 Jan 31;e0245722.
doi: 10.1128/spectrum.02457-22. Online ahead of print.
Cell-Free Dot Blot: an Ultra-Low-Cost and Practical Immunoassay Platform for Detection of Anti-SARS-CoV-2 Antibodies in Human and Animal Sera
Masoud Norouzi[SUP] #[/SUP][SUP] 1 [/SUP], Thang Truong[SUP] #[/SUP][SUP] 2 [/SUP], Katariina Jaenes[SUP] 1 [/SUP], Bryce M Warner[SUP] 2 [/SUP], Robert Vendramelli[SUP] 2 [/SUP], Kevin Tierney[SUP] 2 [/SUP], Darwyn Kobasa[SUP] 2 [/SUP], Nikesh Tailor[SUP] 3 [/SUP], Pamela Plant[SUP] 4 [/SUP], Claudia Dos Santos[SUP] 4 5 [/SUP], Shawn Babiuk[SUP] 3 [/SUP], Aruna Ambagala[SUP] 3 [/SUP], Keith Pardee[SUP] 1 6 [/SUP]
Affiliations
Abstract
Since its emergence in late 2019, the coronavirus disease 2019 (COVID-19) pandemic has caused severe disruption to key aspects of human life globally and highlighted the need for timely, adaptive, and accessible pandemic response strategies. Here, we introduce the cell-free dot blot (CFDB) method, a practical and ultra-low-cost immune diagnostic platform capable of rapid response and mass immunity screening for the current and future pandemics. Similar in mechanism to the widely used enzyme-linked immunosorbent assays (ELISAs), our method is novel and advantageous in that (i) it uses linear DNA to produce the target viral antigen fused to a SpyTag peptide in a cell-free expression system without the need for traditional cloning and antigen purification, (ii) it uses SpyCatcher2-Apex2, an Escherichia coli-produced peroxidase conjugate as a universal secondary detection reagent, obviating the need for commercial or sophisticated enzyme conjugates, and (iii) sera are spotted directly on a nitrocellulose membrane, enabling a simple "dipping" mechanism for downstream incubation and washing steps, as opposed to individual processing of wells in a multiwell plate. To demonstrate the utility of our method, we performed CFDB to detect anti-severe acute respiratory syndrome coronavirus 2 nucleocapsid protein antibodies in precharacterized human sera (23 negative and 36 positive for COVID-19) and hamster sera (16 negative and 36 positive for COVID-19), including independent testing at a collaborating laboratory, and we show assay performance comparable to that of conventional ELISAs. At a similar capacity to 96-well plate ELISA kits, one CFDB assay costs only ~$3 USD. We believe that CFDB can become a valuable pandemic response tool for adaptive and accessible sero-surveillance in human and animal populations. IMPORTANCE The recent COVID-19 pandemic has highlighted the need for diagnostic platforms that are rapidly adaptable, affordable, and accessible globally, especially for low-resource settings. To address this need, we describe the development and functional validation of a novel immunoassay technique termed the cell-free dot blot (CFDB) method. Based on the principles of cell-free synthetic biology and alternative dot blotting procedures, our CFDB immunoassay is designed to provide for timely, practical, and low-cost responses to existing and emerging public health threats, such as the COVID-19 pandemic, at a similar throughput and comparable performance as conventional ELISAs. Notably, the molecular detection reagents used in CFDB can be produced rapidly in-house, using established protocols and basic laboratory infrastructure, minimizing reliance on strained commercial reagents. In addition, the materials and imaging instruments required for CFDB are the same as those used for common Western blotting experiments, further expanding the reach of CFDB in decentralized facilities.
Keywords: COVID-19; cell-free dot blot; immunoassays; immunodiagnostics; infectious disease; pandemic response; public health; synthetic biology; veterinary immunology; viral antigens.
. 2023 Jan 31;e0245722.
doi: 10.1128/spectrum.02457-22. Online ahead of print.
Cell-Free Dot Blot: an Ultra-Low-Cost and Practical Immunoassay Platform for Detection of Anti-SARS-CoV-2 Antibodies in Human and Animal Sera
Masoud Norouzi[SUP] #[/SUP][SUP] 1 [/SUP], Thang Truong[SUP] #[/SUP][SUP] 2 [/SUP], Katariina Jaenes[SUP] 1 [/SUP], Bryce M Warner[SUP] 2 [/SUP], Robert Vendramelli[SUP] 2 [/SUP], Kevin Tierney[SUP] 2 [/SUP], Darwyn Kobasa[SUP] 2 [/SUP], Nikesh Tailor[SUP] 3 [/SUP], Pamela Plant[SUP] 4 [/SUP], Claudia Dos Santos[SUP] 4 5 [/SUP], Shawn Babiuk[SUP] 3 [/SUP], Aruna Ambagala[SUP] 3 [/SUP], Keith Pardee[SUP] 1 6 [/SUP]
Affiliations
- PMID: 36719206
- DOI: 10.1128/spectrum.02457-22
Abstract
Since its emergence in late 2019, the coronavirus disease 2019 (COVID-19) pandemic has caused severe disruption to key aspects of human life globally and highlighted the need for timely, adaptive, and accessible pandemic response strategies. Here, we introduce the cell-free dot blot (CFDB) method, a practical and ultra-low-cost immune diagnostic platform capable of rapid response and mass immunity screening for the current and future pandemics. Similar in mechanism to the widely used enzyme-linked immunosorbent assays (ELISAs), our method is novel and advantageous in that (i) it uses linear DNA to produce the target viral antigen fused to a SpyTag peptide in a cell-free expression system without the need for traditional cloning and antigen purification, (ii) it uses SpyCatcher2-Apex2, an Escherichia coli-produced peroxidase conjugate as a universal secondary detection reagent, obviating the need for commercial or sophisticated enzyme conjugates, and (iii) sera are spotted directly on a nitrocellulose membrane, enabling a simple "dipping" mechanism for downstream incubation and washing steps, as opposed to individual processing of wells in a multiwell plate. To demonstrate the utility of our method, we performed CFDB to detect anti-severe acute respiratory syndrome coronavirus 2 nucleocapsid protein antibodies in precharacterized human sera (23 negative and 36 positive for COVID-19) and hamster sera (16 negative and 36 positive for COVID-19), including independent testing at a collaborating laboratory, and we show assay performance comparable to that of conventional ELISAs. At a similar capacity to 96-well plate ELISA kits, one CFDB assay costs only ~$3 USD. We believe that CFDB can become a valuable pandemic response tool for adaptive and accessible sero-surveillance in human and animal populations. IMPORTANCE The recent COVID-19 pandemic has highlighted the need for diagnostic platforms that are rapidly adaptable, affordable, and accessible globally, especially for low-resource settings. To address this need, we describe the development and functional validation of a novel immunoassay technique termed the cell-free dot blot (CFDB) method. Based on the principles of cell-free synthetic biology and alternative dot blotting procedures, our CFDB immunoassay is designed to provide for timely, practical, and low-cost responses to existing and emerging public health threats, such as the COVID-19 pandemic, at a similar throughput and comparable performance as conventional ELISAs. Notably, the molecular detection reagents used in CFDB can be produced rapidly in-house, using established protocols and basic laboratory infrastructure, minimizing reliance on strained commercial reagents. In addition, the materials and imaging instruments required for CFDB are the same as those used for common Western blotting experiments, further expanding the reach of CFDB in decentralized facilities.
Keywords: COVID-19; cell-free dot blot; immunoassays; immunodiagnostics; infectious disease; pandemic response; public health; synthetic biology; veterinary immunology; viral antigens.